ARGX

925.7001.73%
AA

Anthony A. Rosenberg

Independent Chairman

Mr. Anthony A. Rosenberg, Msc., also known as Tony, serves as Independent Director at Oculis Holding AG since April 2018 and serves as its Independent Chairman since April 2018. He serves as a Vice Chairman since May 27, 2025 and was Non-Executive Director until May 27, 2025 of argenx SE. He was the Executive Partner at MPM Capital. He served as Managing Director of MPM Capital from April 2015 to April 2020. He joined MPM Capital on April 2, 2015. He has been Director of Cullinan Mica Corp. Mr. Rosenberg has been Non-Executive Chairman at Oculis ehf since September 2018. Mr. Rosenberg serves as an Independent Chairman of the Board at Cullinan Therapeutics, Inc. (formerly known as Cullinan Oncology, Inc.) since April 2020 and has been its Independent Director since August 2017. Mr. Rosenberg was Advisor of Serodus ASA since January 19, 2016. He served as the Global Head of Business Development and Licensing at Novartis AG since 2005. From January 2012 to February 2015, Mr. Rosenberg served as Corporate Head of M&A and Licensing at Novartis. He managed over 30 major in-licensing transactions across therapeutic areas as well as numerous divestments. In 2010, he assumed added responsibility leading the Molecular Diagnostics Group. He also served as the Global Head of M&A and Licensing (Corporate) at Novartis AG from January 2013 until February 2015. Mr. Rosenberg serves as the Chief Executive Officer of TR Advisory Services GmbH. He oversaw the Novartis portfolio transformation to focus Novartis on its global businesses in innovative pharmaceuticals, eye care and generics. Mr. Rosenberg served as the Head of Transplantation & Immunology at Novartis AG from 2001 to April 1, 2005. He was Global Head of The Transplant and Immunology Business Unit at Novartis from 2000 to 2005. He initially joined Sandoz in 1980. He served in various leading positions with Sandoz UK. He had been Independent Director of Radius Health, Inc., since March 2, 2015 until December 31, 2020. He served as a Director of Clinical Ink, Inc. He serves as Director of SiO2 Material Science, iOmx Therapeutics and TriNetX. He served as a Director of Idenix Pharmaceuticals Inc., from December 2012 to June 5, 2014 and Idenix Pharmaceuticals Inc., from June 2009 to March 2012. Mr. Rosenberg holds a Master of Science in Physiology from the University of London and a Bachelor of Science in Biological Sciences from the University of Leicester.

Positions